Printer Friendly

Drug-eluting stents found to be superior in efficacy to bare metal stents.

Byline: ANI

London, May 7 (ANI): A study suggests that the use of drug-eluting stents on heart attack patients undergoing angioplasty is more effective and as safe as that of bare-metal stents.

Lead researcher Dr. Gregg W. Stone, a professor of medicine at Columbia University Medical Center/New York-Presbyterian Hospital, has revealed that in patients undergoing angioplasty, the use of paclitaxel-eluting stents has been found to reduce rates of target lesion revascularization (TLR) and binary angiographic restenosis when compared to the use of bare-metal stents after 1 year.

The study also revealed that the primary safety measure of major adverse cardiovascular events (MACE)-including death, reinfarction, stent thrombosis and stroke-established the non-inferiority of drug-eluting stents with respect to safety through 1 year.

The trial enrolled 3,602 heart attack patients at 123 centers in 11 countries, 3,006 of whom were randomised to paclitaxel-eluting stents versus otherwise identical bare metal stents.

During the trial, the use of paclitaxel-eluting stents resulted in a significant reduction of ischemia-driven target-lesion revascularization (TLR)-the rate at which a particular lesion re-narrows following stent implantation severely enough to require either a repeat angioplasty or bypass surgery operation-at 12 months.

The use of paclitaxel-eluting stents also resulted in a significant reduction in binary restenosis after 13 months, which is the rate at which the artery re-narrows at least 50 per cent following implantation of the stent, and was the secondary efficacy endpoint of the trial. The paclitaxel-eluting stent had a rate of 10 per cent and the bare metal stent had a rate of 22.9 per cent.

"Outcomes from prior registry and randomised trials of drug-eluting stents compared to bare metal stents in heart attack patients have been conflicting. These results now provide definitive evidence that paclitaxel-eluting stents are superior in efficacy to bare metal stents and have a comparable safety profile at 1 year," said Dr. Stone.

The researchers believe that the findings of their study will have a major impact on how decisions are made regarding drug-eluting and bare metal stents in the highest risk patients, those in the early hours of a heart attack.

"This study removes much of the uncertainty and concern about the efficacy and safety of drug-eluting stents in this clinical setting. Moreover, all of the patients in this trial will be followed long-term to ensure that these favorable results are maintained," said Dr. Stone.

A research article on the trial has been published in The New England Journal of Medicine. (ANI)

Copyright 2009 Asian News International (ANI) - All Rights Reserved.

Provided by Syndigate.info an Albawaba.com company
COPYRIGHT 2009 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Asian News International
Date:May 27, 2009
Words:430
Previous Article:Exam success depends as much on confidence as on IQ.
Next Article:Emirates Post Office to act as Flydubai's selling agent.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters